Elcin Barker Ergun

Last updated

Elcin Barker Ergun is a business leader in the pharmaceutical industry. [1] In September 2019 she was appointed chief executive officer and member of the board of directors of the Italian company Menarini Group. [2] [3] [4]

Biography

Ergun graduated from TED Ankara College (high school) in Turkey, where she also played basketball and handball and was a member of the team that won the national championship three times. Elcin has a Bachelor of Science degree in computer engineering from Middle East Technical University in Ankara and an MBA from INSEAD (Institut Europeen d’Administration Des Affaires). [5]

Ergun's career started as a software engineer, working for five years in IT management in Amsterdam for ITT Corporation. [6] After her MBA in France, Ergun moved to the UK, leading marketing and supply chain projects at the Northern European head office of Honeywell [6] and later continued as subsidiary chief financial officer. [6] Ergun entered the pharmaceutical industry as chief financial officer of the Turkish subsidiary of GlaxoSmithKline. [7]

After joining Merck KGaA's Healthcare business, [2] [5] [7] Elcin took on roles of increasing seniority within the organisation becoming Executive Vice President and Head of Global Commercial for Merck Serono, [6] achieving significant leadership and business transformation across global commercial operations. [6] This followed her role as Senior Vice President and Head of Intercontinental Region, across the Middle East, Africa, and Russia/CIS countries.

Before she joined Menarini Group, Elcin was based in Boston [5] [8] for three years as Executive Vice President, [5] Head of New Businesses [5] [8] at Merck Healthcare. [9]

Under Ergun's leadership, Menarini has accomplished milestones such as the 2020 acquisition of Stemline Therapeutics, [10] a U.S. commercial-stage biopharmaceutical company, [11] formerly a public listed organization quoted on NASDAQ, [10] focused on the development and commercialization of novel oncology therapeutics. [10] [11]

Related Research Articles

<span class="mw-page-title-main">Merck Group</span> German multinational science and technology company

The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.

<span class="mw-page-title-main">Titan Pharmaceuticals</span>

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

CHI-California Healthcare Institute is a private, non-profit public policy research and advocacy organization, representing more than 250 universities, academic research centers, biotechnology, and medical device companies. Founded in 1993, and based in La Jolla, California, CHI has offices in Washington, D.C., and Sacramento, California. CHI publishes an annual California Biomedical Industry report, providing data on the scope and scale of academic and commercial life sciences research and development within the state. In 2008, the industry employed more than 270,000 Californians and produced revenues in excess of $75 billion.

The Menarini Group is an Italian pharmaceutical company. Its headquarters is in Florence, Tuscany, and it has three divisions: Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics. It develops pharmacological solutions for cardiovascular diseases, oncology, pain/inflammation, asthma and anti-infectives. Menarini's research activities are carried out through Menarini Ricerche, which deals with all R&D activities, from the creation of new projects to drug registration. Its Menarini Biotech follows the creation of a biotechnological drug from the very early stages of research, through to the pilot scale and up to industrial production. The Group's Menarini Diagnostics division is a healthcare company with a worldwide network of affiliates partners and distributors focused on diabetes, haematology, clinical chemistry, urinalysis, and immunology. In 2020, the company had 17,650 employees worldwide.

<span class="mw-page-title-main">Heather Bresch</span> American business executive

Heather Bresch is an American business executive. In 2012, she was named as the chief executive officer (CEO) of Netherlands-based pharmaceutical company Mylan, becoming the first woman to run a Fortune 500 pharmaceutical company. Bresch retired in 2020, upon the closing of Mylan’s combination with Upjohn. Bresch has been a central figure in two controversies: a 2007 accusation of inflating her resume with an unearned MBA degree, and as the CEO of Mylan during the 2016 controversy over pricing of the company's EpiPen products. In 2015, she was listed as #22 in Fortune magazine's “Most Powerful Women” list.

<span class="mw-page-title-main">Merck & Co.</span> American multinational pharmaceutical company

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.

<span class="mw-page-title-main">Apricus Biosciences</span>

Apricus Biosciences, Inc. is a San Diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology.

<span class="mw-page-title-main">Joseph Jimenez</span>

Joseph Jimenez is the former CEO of the Swiss pharmaceutical company Novartis.

<span class="mw-page-title-main">Alex Gorsky</span> American businessman (born 1960)

Alex Gorsky is an American businessman. He is the former chairman and CEO of Johnson & Johnson. Gorsky stepped down as CEO of Johnson & Johnson in January 2022 and was succeeded by Joaquin Duato. He was the seventh person who served as the company's chairman and chief executive officer since it became a publicly traded company in 1944. He is a board director of Apple and JP Morgan Chase.

OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq.

<span class="mw-page-title-main">Karl-Ludwig Kley</span> German manager

Karl-Ludwig Kley is a German business executive.

The Institute for Clinical and Economic Review (ICER) is a Boston-based independent nonprofit organization that seeks to place a value on medical care by providing comprehensive clinical and cost-effectiveness analyses of treatments, tests, and procedures.

<span class="mw-page-title-main">Michael Bonney</span> American businessman and former pharmaceutical executive

Michael "Mike" Weston Bonney is an American businessman and former pharmaceutical executive. Bonney was the president and chief executive officer of Cubist Pharmaceuticals, from 2003 until his retirement in 2014 coinciding with the company being acquired by Merck & Co. for $9.5 billion.

David Meek is an American businessman. He held various global executive positions in major pharmaceutical and biotechnology companies.

Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy.

<span class="mw-page-title-main">Benjamin Breier</span> American businessman

Benjamin Breier was chief executive office and a member of the board of directors of Kindred Healthcare from March 2015 through December 2021. He serves on the board for the Federation of American Hospitals.

<span class="mw-page-title-main">Burke W. Whitman</span> United States Marine Corps general

Burke W. Whitman is an American executive, board director, and former United States Marine Corps general. He serves and leads national and global organizations in business, civil society, and national service.

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.

N. Anthony Coles is an American physician, biotechnology entrepreneur, and pharmaceutical leader. Since 2018, Coles has served as chair of the board of directors for Cerevel Therapeutics.

References

  1. ↑ "Revitalizing Purpose: Q&A with Elcin Barker Ergun | Thought Leadership". Russell Reynolds Associates. Retrieved 2021-07-18.
  2. 1 2 "Menarini: Elcin Barker Ergun amministratore delegato Gruppo". 12 September 2019.
  3. ↑ "Elcin Barker Ergun, A Menarini Indus Farmaceutiche: Profile and Biography". Bloomberg News .
  4. ↑ "Menarini appoints new chief executive". thepharmaletter.com. Retrieved 2021-07-18.
  5. 1 2 3 4 5 marchitto (2020-12-14). "Menarini: Elcin Barker Ergun Group CEO". Adnkronos. Retrieved 2021-04-22.
  6. 1 2 3 4 5 "Keynote speaker - Elcin Ergun | HBA". hbanet.org. Retrieved 2021-04-22.
  7. 1 2 AG, BIOCOM. "Elcin Barker Ergun becomes Menarini CEO". european-biotechnology.com. Retrieved 2021-04-22.
  8. 1 2 Volonté, Chiara (2019-09-16). "Menarini: la via all'internazionalizzazione è donna". Industria Italiana (in Italian). Retrieved 2021-08-31.
  9. ↑ "Vibrant Science & Technology - EMD Group". merckgroup.com. Retrieved 2021-08-31.
  10. 1 2 3 "Menarini Group Completes Acquisition of Stemline Therapeutics - ANSA.it". ansa.it. Retrieved 2021-08-31.
  11. 1 2 "About Us". Stemline Therapeutics. Retrieved 2021-08-31.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.